FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/10/075864 [Registered on: 25/10/2024] Trial Registered Prospectively
Last Modified On: 18/10/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Nutraceutical 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Clinical study to check effectiveness of prebiotic colon detox shots in management of digestive health. 
Scientific Title of Study   A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of prebiotic colon detox shots in promoting digestive health and gut function. 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
MHC/CT/24-25/034 Version 1.00,dated 26th Sept 2024  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ketan Kshirsagar 
Designation  Principal Investigator 
Affiliation  Sangvi Multispeciality Hospital Pvt. Ltd 
Address  Sangvi Multispeciality Hospital, OPD room no 01,1st floor,Krushna Chowk, Krushna Nagar, New Sangvi

Pune
MAHARASHTRA
411027
India 
Phone  9049002749  
Fax  -  
Email  drketan.sangvihospital@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Abhishek Kanade 
Designation  Senior Manager-Research and Product Development 
Affiliation  Seven Turns Pvt. Ltd. 
Address  Seven Turns Pvt Ltd - The Good Bug 204, Naman Midtown Tower A, Senapati Bapat Marg, Prabhadevi West

Mumbai
MAHARASHTRA
400013
India 
Phone  7776018666  
Fax  -  
Email  dr.abhishek@seventurns.in  
 
Details of Contact Person
Public Query
 
Name  Kaynat Mirajkar 
Designation  Lead-Nutrition, Regulatory and Medical Affairs 
Affiliation  Seven Turns Pvt. Ltd. 
Address  Seven Turns Pvt Ltd - The Good Bug 204, Naman Midtown Tower A, Senapati Bapat Marg, Prabhadevi West

Mumbai
MAHARASHTRA
400013
India 
Phone  9699384096  
Fax  -  
Email  kaynat@seventurns.in  
 
Source of Monetary or Material Support  
Seven Turns Pvt. Ltd. The Good Bug 204, Naman Midtown Tower A, Senapati Bapat Marg, Prabhadevi West, Mumbai, Maharashtra 400013 
 
Primary Sponsor  
Name  Seven Turns Pvt. Ltd. 
Address  204, Naman Midtown Tower A, Senapati Bapat Marg, Prabhadevi West, Mumbai, Maharashtra 400013 
Type of Sponsor  Other [Nutraceutical Marketing company ] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ketan Kshirsagar  Sangvi Multispeciality Hospital Pvt. Ltd  OPD room no 01, 1st floor,Krushna Chowk, Krushna Nagar, New Sangvi
Pune
MAHARASHTRA 
9049002749
-
drketan.sangvihospital@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee Sangvi Multispeciality Hospital  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K929||Disease of digestive system, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Group A: Prebiotic Colon Detox Shots  70ml to be taken first thing in the morning on an empty stomach for 14 days. 
Comparator Agent  Group B: Placebo  70ml to be taken first thing in the morning on an empty stomach for 14 days. 
 
Inclusion Criteria  
Age From  20.00 Year(s)
Age To  45.00 Year(s)
Gender  Both 
Details  1.Males and females aged 20-45 years, with an equal gender distribution (both inclusive);2.Female participants will be screened within 2 days of completion of the menstrual phase (bleeding phase). A 7-day screening period will follow to ensure eligibility. Treatment will begin immediately after the screening period is completed. 3.Participants must report one or more gut health-related symptoms, indicated by a GSRS score of 3-5 or a BSFS score of 1-3. Eligible symptoms include:•Bloating •Abdominal discomfort or pain •Infrequent bowel movements (fewer than three defecations per week) •Hard or lumpy stools (types 1 to 3 on the Bristol Stool Form Scale) •Sensation of incomplete evacuation during defecation.4.Participants in whom loose stools are rarely present without the use of laxatives;5.Participants on stable medication for the past three months (with no worsening of symptoms or hospitalization) are eligible, or may be enrolled at the discretion of the investigator;6.Participants should agree to undergo Liver Function Tests and C-reactive protein assessments;7.Willingness to undergo baseline and follow-up assessments of gut health using the GSRS;8.Participants providing voluntary, written informed consent to participate in the study. 
 
ExclusionCriteria 
Details  1.Participants with a diagnosis of colonic inertia;
2.Participants with a history of surgical interventions within the last six months;
3.History of anorectal surgery;
4.Participants diagnosed with functional gastrointestinal disorders including Functional Constipation Irritable Bowel Syndrome (IBS) Inflammatory Bowel Disease (IBD) or chronic diarrhea;
5.Participants with structural abnormalities such as rectal prolapse, rectocele, or anorectal stricture;
6.Participants with untreated or uncontrolled systemic conditions, including HIV or diabetes mellitus or tuberculosis;
7.Participants with renal or liver dysfunction;
8.Participants with neurological disorders, such as Parkinsons disease or multiple sclerosis;
9.A medical history of hypothyroidism, Grade 2 obesity, morbid obesity, or constipation associated with premenopausal or postmenopausal status;
10.Participants currently using laxatives, antacids, proton pump inhibitors, antibiotics, or other probiotic products;
11.Participants using herbal supplements, dietary fiber, or phytonutrient supplements;
12.Participants will be excluded if they have initiated new micronutrient supplements eg iron, zinc within the past 14 days;
13.Participants who have undergone colonic cleansing in the last three months;
14.Pregnant or lactating women, as well as women of childbearing potential who are not using contraception or intending to conceive during the study;
15.Participants with a history of substance abuse or heavy use of alcohol and drugs or tobacco use, where participants smoke more than 1or 2 pack per day;
16.Any other clinical condition in the investigators judgment finds the study participation unsuitable for the participant. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Case Record Numbers 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
1. Gastrointestinal Symptom Rating Scale GSRS Assessment of symptoms including bloating, abdominal pain, diarrhea, and constipation, abdominal discomfort using a 7 Likert scale
Up to three loose stools or bathroom visits per day will be recorded as no to minor discomfort on the GSRS. If the number of loose stools or visits exceeds three, the severity of discomfort will be assessed and scored at the discretion of the investigator.
2. Stool Consistency and Frequency
a. Bristol Stool Form Scale BSFS Evaluating stool consistency
b. Frequency of Bowel Movements Self-reported daily bowel movements recorded using a bowel diary
3. Time of Evacuation Documenting the duration of each bowel movement using a bowel diary
 
1. At day 1, day 4, day 8, and day 15.
2. a. At screening, day 1, day 4, day 8, and day 15.
b. At day 1, day 4, day 8 and day 15.
3. At day 1, day 4, day 8, and day 15.
 
 
Secondary Outcome  
Outcome  TimePoints 
The secondary objectives will be to evaluate the impact of prebiotic colon detox shots on detoxification, and systemic inflammation related to gut health, digestive function, and quality of life.
Additionally, the study will assess safety through monitoring adverse events, tolerability, and compliance throughout the study duration.

 
From Screening to end of the study.
 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "63"
Final Enrollment numbers achieved (India)="63" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   29/10/2024 
Date of Study Completion (India) 01/01/2025 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="0"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

The rationale for conducting the proposed study on the efficacy and safety of prebiotic supplementation in individuals depend on several factors. The gut microbiota, once established, undergoes dynamic changes throughout a person’s life. Despite its variability, alterations in gut microbiota composition have profound implications for the development of various diseases, ranging from chronic gastrointestinal disorders to neurological conditions (55). It is important to evaluate gut microbiota composition and its relationship with the human health–disease condition, as well as the effect of consumption of prebiotic supplement on the balance of its composition. There is growing evidence suggesting that alterations in the gut microbiota composition (dysbiosis), may give rise to various digestive issues such as irritable bowel syndrome, constipation, diarrhea, heartburn, or bloating.

The prevalence of GI diseases has increased in recent years, largely attributed to significant lifestyle changes. Studies have revealed a strong association between GI disorders and mental health issues, including depression, stress, anxiety, and impaired central nervous system function (56). While dietary interventions are a cornerstone of gut health and inflammation management, long-term success is often challenging to achieve. Therefore, exploring adjunct approach such as prebiotic and gut detox supplementation could offer additional strategies for improving gut detoxification and digestion, potentially influencing metabolic outcomes. Boosting the beneficial bacteria in the digestive tract and gut detoxification help to provide relief from digestive issues. Undergoing gut cleansing i.e. detoxification improves digestion, repairs existing damage to the intestines and restore healthy intestinal function.

Moreover, evaluating the safety of prebiotic supplementation is essential particularly in gut health and inflammation management where individuals may have underlying health conditions or be taking multiple medications. If interventional supplement is found to be effective and safe alternative, they could be incorporated into treatment protocols of various gastric disorders, offering participant s additional options for achieving and maintaining digestive health.

Overall, this randomized, double-blind, placebo-controlled clinical trial investigating the efficacy of prebiotic colon detox shots would fill a significant knowledge gap in the field of digestive health and gut function. The findings could contribute to a better understanding of the population health burden associated with digestive diseases and inform the development of strategies to reduce the overall disease burden. The major goals of the investigational product are to reduce inflammation, support gut health, and improve digestion by removing inflammatory foods and replacing them with nourishing, digestible options. Additionally, the product seeks to consolidate the positive changes achieved during the cleanse by promoting long-term gut health through balanced nutrition and healthy lifestyle practices.

 


 
Close